P27 ubiquitination assay and methods of use

• US 20060194262A1
• Filed: 10/17/2005
• Published: 08/31/2006
• Est. Priority Date: 10/15/2004
• Status: Abandoned Application

• Current Assignee: Frank M. Mercurio, Sarah Cox, Shuichan Xu, Weilin Xie
• Original Assignee: Frank M. Mercurio, Sarah Cox, Shuichan Xu, Weilin Xie
• Inventors: Cox, Sarah, Mercurio, Frank M., Xu, Shuichan, Xie, Weilin
• Application Number:
  US11/253,128
• Publication Number:
  US 20060194262A1
• Time in Patent Office: Days
• US Class Current: 435/7.5
• CPC Class Codes: C12Q 1/25 involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6842 Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

This invention relates to easy and reliable assays for the ubiquitination of p27. Because the assay can be performed as a plate capture assay, or as a homogenous time-resolved fluorescence resonance energy transfer assay, with defined, easily replicatable reaction conditions, it is particularly useful for high-throughput screening of, for example, a prospective anticancer agent. The invention provides methods to determine the amount of ubiquitination of p27, or of any protein, and use of the method to identify compounds that modulate the ubiquitination of p27, or any protein.

Claims

1. A method of determining the amount of ubiquitination of a protein, comprising:

a. contacting said protein with a plurality of polypeptides, said plurality of polypeptides together capable of ubiquitinating said protein, to form ubiquitinated protein;

b. capturing said ubiquitinated protein on a surface; and

c. determining an amount of ubiquitin present in said protein captured on said surface, wherein the amount of ubiquitin present in said protein captured on said surface is correlated with the amount of ubiquitination of said protein.

2. The method of claim 1, wherein said protein is p27.

3. The method of claim 1, wherein said plurality of polypeptides are each isolated polypeptides.

4. The method of claim 1, wherein said plurality of polypeptides comprises E1, E2, E3, Cks1 and ubiquitin.

5. The method of claim 2, wherein said E1, E2, E3 or Cks1 is recombinantly produced.

6. The method of claim 2, wherein said E1, E2, E3 and Cks1 are purified from a cell extract.

7. The method of claim 4, wherein said ubiquitin is labeled.

8. The method of claim 7, wherein said label is biotin.

9. The method of claim 7 wherein said labeled ubiquitin is visualized with Europium that is coupled to streptavidin.

10. The method of claim 1, wherein the determination occurs in a multi-well plate as part of a high-throughput screen.

11. A method of identifying a compound that modulates ubiquitination of p27, comprising determining the amount of ubiquitinated p27 formed by combining of isolated phosphorylated p27, E1, E2, E3, Cks1 and ubiquitin in the presence of said compound and in the absence of said compound, wherein, if the amount of ubiquitinated p27 formed in the presence of said compound differs from the amount of ubiquitinated p27 formed in the absence of said compound, said compound is identified as a compound that modulates the ubiquitination of p27.

12. The method of claim 11, wherein said p27 is phosphorylated with Cdk2 and Cyclin E prior to combination with said E1, E2, E3, Cdk2 and ubiquitin.

13. The method of claim 11, wherein said phosphorylated p27 is present at a concentration of about 4 ng/μ

L;

said E1 is present at a concentration of about 5 ng/μ

L;

said E2 is present at a concentration of about 150 ng/μ

L;

or said E3 is present at a concentration of about 5 ng/μ

L.

14. The method of claim 11, wherein said amount of ubiquitinated p27 formed in the presence of said compound is lower the amount of ubiquitinated p27 formed in the absence of said compound, and said compound is identified as a compound that inhibits the ubiquitination of p27.

15. The method of claim 11, wherein said E1, E2, E3 or Cks1 are recombinantly produced.

16. The method of claim 11, wherein said E1, E2, E3 or Cks1 are purified from a cell extract.

17. The method of claim 11, wherein said ubiquitin is labeled with a label.

18. The method of claim 17, wherein said label is biotin.

19. The method of claim 17, wherein said labeled ubiquitin is visualized using Europium labeled streptavidin.

20. The method of claim 11, wherein the identification occurs in a multi-well plate as part of a high-throughput screen.

21. A method of determining the amount of ubiquitin in a ubiquitinated protein, comprising:

a. labeling said protein with a first label;

b. labeling said ubiquitin with a second label;

c. determining a ratio of said second label to said first label, wherein a higher ratio indicates a greater amount of ubiquitination of said protein.

22. The method of claim 21, wherein said protein is p27.

23. The method of claim 21, wherein said first label and said second label are fluorescent labels.

24. The method of claim 21, wherein said determining a ratio comprises detecting fluorescence from said first label to produce a first fluorescence value;

detecting fluorescence from said second label to produce a second fluorescence value; and

determining the ratio of said first fluorescence value to said second fluorescence value.

25. The method of claim 21 wherein said second label emits a detectable fluorescence signal when said first fluorescent label is excited.

26. The method of claim 21 wherein said first label and said second label are present on the same ubiquitinated p27.

27. The method of claim 26 wherein said first label emits a detectable fluorescence signal when said second fluorescent label is excited.

28. The method of claim 27 wherein said first label and said second label are present on the same ubiquitinated p27.

29. The method of claim 21, wherein said first label and said second label are suitable for use in a fluorescence resonance energy transfer assay.

30. The method of claim 21, wherein said first label is Europium, Cy5, trisbipyridine europium cryptate, Dylight™

547, Dylight™

647, or allophycocyanine (XL665).

31. The method of claim 21, wherein said second label is Europium, Cy5, trisbipyridine europium cryptate, Dylight™

547, Dylight™

647, or allophycocyanine (XL665).

32. The method of claim 21, wherein said first label is Europium and said second label is Cy5.

33. The method of claim 32, wherein said Europium is excited by radiation at 340 nm, the fluorescence of said Europium at 620 nm is determined to produce a first fluorescence value, the fluorescence of said Cy5 at 665 nm is determined to produce a second fluorescence value, and a ratio of the second fluorescence value to the first fluorescence value is determined, wherein a higher ratio indicates a greater amount of p27 ubiquitination.

34. A method of identifying an anticancer agent, comprising determining the amount of ubiquitinated p27 formed by combining isolated p27, E1, E2, E3, Cks 1, Cyclin E, Cdk2 and ubiquitin in the presence of said compound and in the absence of said compound;

wherein, if the amount of ubiquitinated p27 formed in the presence of said compound differs from the amount of ubiquitinated p27 formed in the absence of said compound, said compound is identified as an anticancer agent.

35. The method of claim 34, wherein said p27 is phosphorylated with Cdk2 and Cyclin E prior to combination with said E1, E2, E3, Cdk2 and ubiquitin.

36. The method of claim 34, wherein said phosphorylated p27 is present at a concentration of about 4 ng/μ

L;

said E1 is present at a concentration of about 5 ng/μ

L;

said E2 is present at a concentration of about 150 ng/μ

L;

or said E3 is present at a concentration of about 7.5 ng/μ

L.

37. The method of claim 34, wherein said amount of ubiquitinated p27 formed in the presence of said compound is lower the amount of ubiquitinated p27 formed in the absence of said compound.

38. The method of claim 34, wherein said E1, E2, E3 or Cks1 are recombinantly produced.

39. The method of claim 34, wherein said E1, E2, E3, and Cks1 are purified from a cell extract.

40. The method of claim 34, wherein said ubiquitin is labeled with a label.

41. The method of claim 40, wherein said label is biotin.

42. The method of claim 40, wherein said labeled ubiquitin is visualized using Europium labeled streptavidin.

43. The method of claim 34, wherein the identification occurs in a multi-well plate as part of a high-throughput screen.

44. A kit for p27 ubiquitination assay comprising p27;

Cdk2/Cyclin E; and

a plurality of polypeptides, said plurality of polypeptides together capable of ubiquitinating p27, recombinant cells expressing the polypeptides, or recombinant vectors harboring sequences which encode the polypeptides.

45. The kit of claim 44, wherein p27 and Cdk2/Cyclin E are provided as a complex.

46. The kit of claim 44, wherein said plurality of polypeptides comprises E1, E2, E3, Cks1 and ubiquitin.

47. The kit of claim 46, wherein said ubiquitin is labeled with a label.

48. The kit of claim 47, wherein said label is biotin.

49. The kit of claim 44, which further comprises one or more of plates, optionally coated with Protein A or G;

buffers;

visualization reagents;

or an apparatus or a reagent required for expression and purification of the polypeptides.